Business Daily Media

Men's Weekly

.

Bionomics Limited participated in the H.C Wainwright BioConnect Conference

  • Written by PR Newswire

ADELAIDE, Australia, Jan. 12, 2022 /PRNewswire/ -- Bionomics Limited (ASX:BNO, NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company, participated in the H.C Wainwright BioConnect Conference that was held virtually from January 10-13, 2022.

Dr Errol De Souza, Executive Chairman of Bionomics, provided an update on the Company including BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor in development for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD), with U.S. Food and Drug Administration (FDA) Fast Track designation for both clinical indications.

The presentation is available on the Company's website https://www.bionomics.com.au/investor-centre/presentations-posters/[1]

FOR FURTHER INFORMATION PLEASE CONTACT:

About Bionomics Limited

Bionomics is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.

www.bionomics.com.au[2]

View original content:https://www.prnewswire.com/news-releases/bionomics-limited-participated-in-the-hc-wainwright-bioconnect-conference-301459281.html[3]

Read more https://www.prnasia.com/story/archive/3628834_CN28834_0

Time to punch above our weight and stop shadowboxing on AI

Australia prides itself on being an innovation economy. We celebrate startups, talk about productivity, and lean into our reputation for punching ...

Colter Bay Capital Launches as Australia’s Newest Institutional Private Credit Fund

Led by seasoned capital markets veteran Mark Wang, the fund is purpose-built to serve Australia’s most productive yet chronically underserved busi...

Global Thryv voices bring a sharper lens to International Women’s Day

Thryv® (NASDAQ: THRY), ANZ’s leading AI-enabled small business marketing software platform provider, marks International Women’s Day (IWD) with a bu...

AI curiosity fuels new wave of employee-led innovation in Australia

Leaders across Australia are asking themselves how they can ensure their employees get the most out of AI. We recently conducted research to help an...

Is your search bar your competitor’s best salesperson?

A few weeks ago, I was watching the Super Bowl. Traditionally, those halftime ad spots are reserved for the world’s biggest, most established bran...

AIIMS Group and AdVisible merge

Two of Australia’s most established independent agencies unite, creating marketing powerhouse backed by three decades of combined experience     ...